Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A controlled, randomized, double-blind phase 1 trial evaluating BT-20 versus placebo in addition to standard supportive treatments, in patients with moderate to severe COVID-19 related ARDS

Next Previous
X
Search
Trial Profile

A controlled, randomized, double-blind phase 1 trial evaluating BT-20 versus placebo in addition to standard supportive treatments, in patients with moderate to severe COVID-19 related ARDS

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 27 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BT-20 (Primary)
  • Indications SARS-CoV-2 acute respiratory disease
  • Focus Adverse reactions
  • Sponsors BioSenic

    • Most Recent Events

    • 20 May 2021 According to a Bone Therapeutics media release, an update on this study will be provided at the International Society for Cell & Gene Therapy (ISCT) Annual Meeting, May 2021.
    • 25 Aug 2020 New trial record
    • 20 Aug 2020 According to a Bone Therapeutics media release, company recieved grants from the Walloon Region (Belgium) for research and initial preparatory steps towards clinical development of BT-20. This funding will use preparation of the submission of the Clinical Trial Application (CTA) to FAMHP for this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top